IGC Pharma, Inc.(IGC)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
IGC Pharma, Inc. (IGC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IGC at 13.6/100 on a 32-signal composite quality model, placing it at rank #2,874 of 2,962 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), IGC Pharma, Inc. reports quarterly revenue of $265.0K, net income of $-2.9M, free cash flow of $-2.6M. Top institutional holders of IGC by reported 13-F value include GEODE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, BlackRock, based on the most recent SEC filings. IGC trades on the NYSE exchange and files with the SEC under CIK 1326205. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IGC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IGC Pharma, Inc. directly from SEC EDGAR.
AI Quality Score
13.6/100
AI Rank
#2,874
Revenue
$265.0K
Net Income
$-2.9M
Free Cash Flow
$-2.6M
IGC key financials by period
IGC Pharma, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-KT
$1.3M
$-7.1M
—
FY 2024
10-K
$1.3M
$-13.0M
—
FY 2023
10-K
$911.0K
$-11.5M
—
FY 2022
10-K
$397.0K
$-15.0M
—
FY 2021
10-K
$898.0K
$-8.8M
—
FY 2020
10-K
$4.1M
$-7.3M
-168.6%
Institutions holding IGC
Institutional investors reporting a position in IGC Pharma, Inc. on SEC Form 13F.
